Betulinic acid-mediated apoptosis in human prostate cancer cells involves p53 and nuclear factor-kappa B (NF-KB) pathways

Molecules

Volumn 22, Issue 2, 2017, Pages

  Shankar, Eswar ^a,b   Zhang, Ailin ^a   Franco, Daniel ^a   Gupta, Sanjay ^a,b,c,d   Katiyar, Santosh K ^e  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e Case Comprehensive Cancer Center ^*

Author keywords

Apoptosis; Betulinic acid; Chemoprevention; Prostate cancer; Triterpenoid

Indexed keywords

ANTINEOPLASTIC AGENT; BAX PROTEIN, HUMAN; BCL2 PROTEIN, HUMAN; BETULIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; TP53 PROTEIN, HUMAN; TRITERPENE;

APOPTOSIS; CELL SURVIVAL; DNA FRAGMENTATION; DRUG EFFECTS; DRUG SCREENING; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; MALE; METABOLISM; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; CELL SURVIVAL; DNA FRAGMENTATION; DRUG SCREENING ASSAYS, ANTITUMOR; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MALE; NF-KAPPA B; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; TRITERPENES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85013200668     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules22020264     Document Type: Article

References (44)

1. Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin. 2011, 61, 69-90.
2. American Cancer Society. Cancer Facts and Figures 2016. Available online: http://www.cancer.org/Cancer/ProstateCancer/index (accessed on 15 December 2016).
3. Sfanos, K.S.; de Marzo, A.M. Prostate cancer and inflammation the evidence. Histopathology 2012, 60, 199-215.
4. Stark, T.; Livas, L.; Kyprianou, N. Inflammation in prostate cancer progression and therapeutic targeting. Transl. Androl. Urol. 2015, 4, 455-463.
5. Lucia, M.S.; Torkko, K.C. Inflammation as a target for prostate cancer chemoprevention: Pathological and laboratory rationale. J. Urol. 2004, 171, S30-S34.
6. Jin, R.J.; Lho, Y.; Connelly, L.; Wang, Y.; Yu, X.; Saint Jean, L.; Case, T.C.; Ellwood-Yen, K.; Sawyers, C.L.; Bhowmick, N.A.; et al. The nuclear Factor-Kappa-B pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res. 2008, 68, 6762-6769.
7. Nguyen, D.P.; Li, J.; Yadav, S.S.; Tewari, A.K. Recent insights into NF-κB signaling pathways and the link between inflammation and prostate cancer. BJU Int. 2014, 114, 168-176.
8. Shukla, S.; MacLennan, G.T.; Fu, P.; Patel, J.; Marengo, S.R.; Resnick, M.I.; Gupta, S. Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia 2004, 6, 390-400.
9. Sweeney, C.; Li, L.; Shanmugam, R.; Bhat-Nakshatri, P.; Jayaprakasan, V.; Baldridge, L.A. Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin. Cancer Res. 2004, 10, 5501-5507.
10. Shukla, S.; Maclennan, G.T.; Marengo, S.R.; Resnick, M.I.; Gupta, S. Constitutive activation of PI3K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model. Prostate 2005, 64, 224-239.
11. Chen, C.D.; Sawyers, C.L. NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol. Cell. Biol. 2002, 22, 2862-2870.
12. Lowe, S.W.; Cepero, E.; Evan, G. Intrinsic tumour suppression. Nature 2004, 432, 307-315.
13. Rivlin, N.; Brosh, R.; Oren, M.; Rotter, V. Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. Genes Cancer 2011, 2, 466-474.
14. Bookstein, R.; MacGrogan, D.; Hilsenbeck, S.G.; Sharkey, F.; Allred, D.C. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res. 1993, 53, 3369-3373.
15. Heidenberg, H.B.; Bauer, J.J.; McLeod, D.G.; Moul, J.W.; Srivastava, S. The role of the p53 tumor suppressor gene in prostate cancer: A possible biomarker? Urology 1996, 48, 971-979.
16. Downing, S.R.; Russell, P.J.; Jackson, P. Alterations of p53 are common in early stage prostate cancer. Can. J. Urol. 2003, 10, 1924-1933.
17. Effert, P.J.; Neubauer, A.; Walther, P.J.; Liu, E.T. Alterations of the P53 gene are associated with the progression of a human prostate carcinoma. J. Urol. 1992, 147, 789-793.
18. Buhmeida, A.; Pyrhönen, S.; Laato, M.; Collan, Y. Prognostic factors in prostate cancer. Diagn. Pathol. 2006, 1, 4.
19. Chappell, W.H.; Lehmann, B.D.; Terrian, D.M.; Abrams, S.L.; Steelman, L.S.; McCubrey, J.A. p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3. Cell Cycle 2012, 11, 4579-4588.
20. Tergaonkar, V. p53 and NF-kappaB fresh breath in the cross talk. Cell Res. 2009, 19, 1313-1315.
21. Schneider, G.; Henrich, A.; Greiner, G.; Wolf, V.; Lovas, A.; Wieczorek, M.; Wagner, T.; Reichardt, S.; von Werder, A.; Schmid, R.M.; et al. Crosstalk between stimulated NF-kappaB and the tumor suppressor p53. Oncogene 2010, 29, 2795-2806.
22. Murphy, S.H.; Suzuki, K.; Downes, M.; Welch, G.L.; de Jesus, P.; Miraglia, L.J.; Orth, A.P.; Chanda, S.K.; Evans, R.M.; Verma, I.M. Tumor suppressor protein p53, is a regulator of NF-kappaB repression by the glucocorticoid receptor. Proc. Natl. Acad. Sci. USA 2011, 108, 17117-17122.
23. Webster, G.A.; Perkins, N.D. Transcriptional cross talk between NF-kappaB and p53. Mol. Cell. Biol. 1999, 19, 3485-3495.
24. Lowe, J.M.; Menendez, D.; Bushel, P.R.; Shatz, M.; Kirk, E.L.; Troester, M.A.; Garantziotis, S.; Fessler, M.B.; Resnick, M.A. p53 and NF-κB coregulate proinflammatory gene responses in human macrophages. Cancer Res. 2014, 74, 2182-2192.
25. Zhang, X.; Hu, J.; Chen, Y. Betulinic acid and the pharmacological effects of tumor suppression (Review). Mol. Med. Rep. 2016, 14, 4489-4495.
26. Rabi, T.; Gupta, S. Dietary terpenoids and prostate cancer chemoprevention. Front. Biosci. 2008, 13, 3457-3469.
27. Zuco, V.; Supino, R.; Righetti, S.C.; Cleris, L.; Marchesi, E.; Gambacorti-Passerini, C.; Formelli, F. Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. Cancer Lett. 2002, 175, 17-25.
28. Fulda, S.; Jeremias, I.; Debatin, K.M. Cooperation of betulinic acid and TRAIL to induce apoptosis in tumor cells. Oncogene 2004, 23, 7611-7620.
29. Selzer, E.; Pimentel, E.; Wacheck, V.; Schlegel, W.; Pehamberger, H.; Jansen, B.; Kodym, R. Effects of betulinic acid alone and in combination with irradiation in human melanoma cells. J. Investig. Dermatol. 2000, 114, 935-940.
30. Chintharlapalli, S.; Papineni, S.; Ramaiah, S.K.; Safe, S. Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res. 2007, 67, 2816-2823.
31. Rabi, T.; Shukla, S.; Gupta, S. Betulinic acid suppresses constitutive and TNFalpha-induced NF-kappaB activation and induces apoptosis in human prostate carcinoma PC-3 cells. Mol. Carcinog. 2008, 47, 964-973.
32. Loughery, J.; Cox, M.; Smith, L.M.; Meek, D.W. Critical role for p53-serine 15 phosphorylation in stimulating transactivation at p53-responsive promoters. Nucleic Acids Res. 2014, 42, 7666-7680.
33. Riley, T.; Sontag, E.; Chen, P.; Levine, A. Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell Biol. 2008, 9, 402-412.
34. Pisha, E.; Chai, H.; Lee, I.S.; Chagwedera, T.E.; Farnsworth, N.R.; Cordell, G.A.; Beecher, C.W.; Fong, H.H.; Kinghorn, A.D.; Brown, D.M. Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat. Med. 1995, 1, 1046-1051.
35. Meng, R.D.; El-Deiry, W.S. p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma. Exp. Cell Res. 2001, 262, 154-169.
36. Fulda, S.; Friesen, C.; Los, M.; Scaffidi, C.; Mier, W.; Benedict, M.; Nuñez, G.; Krammer, P.H.; Peter, M.E.; Debatin, K.M. Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res. 1997, 57, 4956-4964.
37. Strasser, A.; Harris, A.W.; Jacks, T.; Cory, S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 1994, 79, 329-339.
38. Luo, J.L.; Kamata, H.; Karin, M. IKK/NF-kappaB signaling: Balancing life and death - A new approach to cancer therapy. J. Clin. Investig. 2005, 115, 2625-2632.
39. Karin, M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441, 431-436.
40. Takada, Y.; Aggarwal, B.B. Betulinic acid suppresses carcinogen-induced NF-kappa B activation through inhibition of I kappa B alpha kinase and p65 phosphorylation: Abrogation of cyclooxygenase-2 and matrix metalloprotease-9. J. Immunol. 2003, 171, 3278-3286.
41. Fulda, S.; Scaffidi, C.; Susin, S.A.; Krammer, P.H.; Kroemer, G.; Peter, M.E.; Debatin, K.M. Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid. J. Biol. Chem. 1998, 273, 33942-33948.
42. Udeani, G.O.; Zhao, G.M.; Geun Shin, Y.; Cooke, B.P.; Graham, J.; Beecher, C.W.; Kinghorn, A.D.; Pezzuto, J.M. Pharmacokinetics and tissue distribution of betulinic acid in CD-1 mice. Biopharm. Drug Dispos. 1999, 20, 379-383.
43. Srivastava, J.K.; Gupta, S. Antiproliferative and apoptotic effects of chamomile extract in various human cancer cells. J. Agric. Food Chem. 2007, 55, 9470-9478.
44. Shukla, S.; Gupta, S. Apigenin-induced prostate cancer cell death is initiated by reactive oxygen species and p53 activation. Free Radic. Biol. Med. 2008, 44, 1833-1845.